190 related articles for article (PubMed ID: 20559781)
1. Nifedipine inhibits cardiac hypertrophy and left ventricular dysfunction in response to pressure overload.
Ago T; Yang Y; Zhai P; Sadoshima J
J Cardiovasc Transl Res; 2010 Aug; 3(4):304-13. PubMed ID: 20559781
[TBL] [Abstract][Full Text] [Related]
2. The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.
Chiang CS; Huang CH; Chieng H; Chang YT; Chang D; Chen JJ; Chen YC; Chen YH; Shin HS; Campbell KP; Chen CC
Circ Res; 2009 Feb; 104(4):522-30. PubMed ID: 19122177
[TBL] [Abstract][Full Text] [Related]
3. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
4. CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes.
MacDonnell SM; Weisser-Thomas J; Kubo H; Hanscome M; Liu Q; Jaleel N; Berretta R; Chen X; Brown JH; Sabri AK; Molkentin JD; Houser SR
Circ Res; 2009 Aug; 105(4):316-25. PubMed ID: 19608982
[TBL] [Abstract][Full Text] [Related]
5. Ca
Baier MJ; Klatt S; Hammer KP; Maier LS; Rokita AG
J Mol Cell Cardiol; 2020 Jan; 138():212-221. PubMed ID: 31836540
[TBL] [Abstract][Full Text] [Related]
6. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
[TBL] [Abstract][Full Text] [Related]
7. Ca(2+) influx through L-type Ca(2+) channels and transient receptor potential channels activates pathological hypertrophy signaling.
Gao H; Wang F; Wang W; Makarewich CA; Zhang H; Kubo H; Berretta RM; Barr LA; Molkentin JD; Houser SR
J Mol Cell Cardiol; 2012 Nov; 53(5):657-67. PubMed ID: 22921230
[TBL] [Abstract][Full Text] [Related]
8. Muscle-specific RING finger 1 negatively regulates pathological cardiac hypertrophy through downregulation of calcineurin A.
Maejima Y; Usui S; Zhai P; Takamura M; Kaneko S; Zablocki D; Yokota M; Isobe M; Sadoshima J
Circ Heart Fail; 2014 May; 7(3):479-90. PubMed ID: 24526353
[TBL] [Abstract][Full Text] [Related]
9. Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling.
Chen Y; Yuan J; Jiang G; Zhu J; Zou Y; Lv Q
Mol Med Rep; 2017 Oct; 16(4):4545-4552. PubMed ID: 28849081
[TBL] [Abstract][Full Text] [Related]
10. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
[TBL] [Abstract][Full Text] [Related]
11. Deletion of Interleukin-6 Attenuates Pressure Overload-Induced Left Ventricular Hypertrophy and Dysfunction.
Zhao L; Cheng G; Jin R; Afzal MR; Samanta A; Xuan YT; Girgis M; Elias HK; Zhu Y; Davani A; Yang Y; Chen X; Ye S; Wang OL; Chen L; Hauptman J; Vincent RJ; Dawn B
Circ Res; 2016 Jun; 118(12):1918-1929. PubMed ID: 27126808
[TBL] [Abstract][Full Text] [Related]
12. Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy.
Chen X; Nakayama H; Zhang X; Ai X; Harris DM; Tang M; Zhang H; Szeto C; Stockbower K; Berretta RM; Eckhart AD; Koch WJ; Molkentin JD; Houser SR
J Mol Cell Cardiol; 2011 Mar; 50(3):460-70. PubMed ID: 21111744
[TBL] [Abstract][Full Text] [Related]
13. CaMKIIδC Drives Early Adaptive Ca
Ljubojevic-Holzer S; Herren AW; Djalinac N; Voglhuber J; Morotti S; Holzer M; Wood BM; Abdellatif M; Matzer I; Sacherer M; Radulovic S; Wallner M; Ivanov M; Wagner S; Sossalla S; von Lewinski D; Pieske B; Brown JH; Sedej S; Bossuyt J; Bers DM
Circ Res; 2020 Oct; 127(9):1159-1178. PubMed ID: 32821022
[TBL] [Abstract][Full Text] [Related]
14. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
[TBL] [Abstract][Full Text] [Related]
15. Exercise preconditioning attenuates pressure overload-induced pathological cardiac hypertrophy.
Xu T; Tang H; Zhang B; Cai C; Liu X; Han Q; Zou L
Int J Clin Exp Pathol; 2015; 8(1):530-40. PubMed ID: 25755743
[TBL] [Abstract][Full Text] [Related]
16. The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy.
Taglieri DM; Johnson KR; Burmeister BT; Monasky MM; Spindler MJ; DeSantiago J; Banach K; Conklin BR; Carnegie GK
J Mol Cell Cardiol; 2014 Jan; 66():27-40. PubMed ID: 24161911
[TBL] [Abstract][Full Text] [Related]
17. Targeting E3 Ubiquitin Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination.
Zhao D; Zhong G; Li J; Pan J; Zhao Y; Song H; Sun W; Jin X; Li Y; Du R; Nie J; Liu T; Zheng J; Jia Y; Liu Z; Liu W; Yuan X; Liu Z; Song J; Kan G; Li Y; Liu C; Gao X; Xing W; Chang YZ; Li Y; Ling S
Circulation; 2021 Aug; 144(9):694-711. PubMed ID: 34139860
[TBL] [Abstract][Full Text] [Related]
18. Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades.
Dai H; Jia G; Liu X; Liu Z; Wang H
Environ Toxicol Pharmacol; 2014 Jul; 38(1):263-71. PubMed ID: 24975447
[TBL] [Abstract][Full Text] [Related]
19. Rho-kinase inhibition reverses impaired Ca
Olgar Y; Celen MC; Yamasan BE; Ozturk N; Turan B; Ozdemir S
Cell Calcium; 2017 Nov; 67():81-90. PubMed ID: 29029794
[TBL] [Abstract][Full Text] [Related]
20. The CaMKII phosphorylation site Thr1604 in the Ca
Li J; Wang S; Zhang J; Liu Y; Zheng X; Ding F; Sun X; Zhao M; Hao L
Channels (Austin); 2020 Dec; 14(1):151-162. PubMed ID: 32290730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
